In this study (NCT02997202), adult patients with FLT3-ITD AML who were treated with HSCT in first remission were assigned to either gilteritinib or placebo for 24 months in the post-HCST maintenance setting; the primary endpoint of RFS was not found to have a statistically significant difference [43]. The gene discussed is FLT3; the disease is acute myeloid leukemia.